Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Basit Öğe Kaydı
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridAksoy, Sercan/0000-0003-4984-1049;
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidAksoy, Sercan/S-2480-2019
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.contributor.authorBilici, Ahmet
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorCubukcu, Erdem
dc.date.accessioned2024-06-12T11:03:10Z
dc.date.available2024-06-12T11:03:10Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.en_US
dc.identifier.doi10.1080/0284186X.2023.2202330
dc.identifier.endpage390en_US
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.issue4en_US
dc.identifier.pmid37083566en_US
dc.identifier.scopus2-s2.0-85153495962en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage381en_US
dc.identifier.urihttps://doi.org/10.1080/0284186X.2023.2202330
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21558
dc.identifier.volume62en_US
dc.identifier.wosWOS:000971681800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofActa Oncologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHER2 Protein Positiveen_US
dc.subjectBreast Canceren_US
dc.subjectNeoadjuvant Treatmenten_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectEvent-Free Survivalen_US
dc.subjectRelapseen_US
dc.subjectReal-Word Evidenceen_US
dc.subjectPathological Complete Responseen_US
dc.subjectControlled Superiority Trialen_US
dc.subjectAdjuvant Trastuzumaben_US
dc.subjectCardiac Safetyen_US
dc.subjectOpen-Labelen_US
dc.subjectNeosphereen_US
dc.subjectRegimensen_US
dc.subjectEfficacyen_US
dc.titleImpact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu